SnagRx vs Pallas Health: Compounded GLP-1s, Price and Care Compared
Quick verdict: If lowest annual compounded pricing and a named 503A pharmacy network matter most, SnagRx leads; if you want clinician choice between brand-name pens and compounded options plus integrated provider check-ins, Pallas Health is stronger. This comparison looks at pricing structure, availability of brand-name versus compounded drugs, clinician and care features, named pharmacy and shipping practices, and refund or guarantee policies to help decide between SnagRx vs Pallas Health.
See SnagRx pricing and plan details
Price models and payment commitments
SnagRx advertises compounded semaglutide from $69/month and tirzepatide from $119/month as 12-month plan rates; month-to-month equivalents are $99 and $149. SnagRx emphasizes a price locked flat at every dose and at renewal for the life of treatment. Pallas Health lists compounded semaglutide at $139 for the first month, then $597 every 12 weeks, which it presents as about $199/month on average; compounded tirzepatide is $179 first month then $897 every 12 weeks, about $299/month average. Pallas also sells FDA-approved brand-name pens at separate cash-pay prices. In short, SnagRx targets cost-driven patients willing to commit to 12 months to access the lowest monthly rate, while Pallas sells a clinician-selected route with a higher intro and renewal cadence for compounded plans.
Price nuance
Both providers state their compounded prices cover medication, clinician review and shipping, but SnagRx explicitly says the $69 and $119 figures are 12-month plan rates. Pallas notes its compounded plans renew every 12 weeks and that intro month pricing differs from renewal amounts.
Brand-name availability versus compounded-only approach
SnagRx offers compounded semaglutide and tirzepatide only and states these are compounded medications produced in FDA-regulated facilities but not FDA-approved finished products. It does not offer branded Wegovy, Ozempic, Mounjaro, or Zepbound. Pallas Health offers both routes from one intake: FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro, and clinician-personalized compounded semaglutide or tirzepatide when a brand medication is not the right fit. If receiving a brand-name pen is a priority, Pallas provides that option; SnagRx does not.
Clinician model, care features, and coverage
SnagRx medical care is delivered by OpenLoop Health, a clinician network it names; it states clinicians typically review intake within five hours and within 24 hours, and that OpenLoop clinicians retain the decision to prescribe. SnagRx highlights clinician review and a full refund if the prescription is declined, plus a stated six-month weight-loss guarantee with terms applied. Pallas uses US-licensed clinicians who choose between brand or compounded medication and includes provider care, ongoing check-ins and care-team messaging inside the plan price with no membership fee. Pallas is 100% online and asynchronous in most states (43 of 50), but a video visit is required in seven states plus Washington, D.C. SnagRx notes clinician network coverage for 48 states; Pallas notes the asynchronous model applies in 43 states.
Pharmacy partners, shipping and operational promises
SnagRx names its four US 503A partner compounding pharmacies and promises next-day UPS or FedEx shipping in temperature-controlled packaging, stating orders ship next-day for approved prescriptions. Pallas states compounded medications are prepared by US-licensed compounding pharmacies and offers free expedited and discreet shipping. Both stress shipment from US compounding pharmacies and that compound appearance may vary from site images. SnagRx emphasizes named pharmacies and a stated quick clinician review window; Pallas emphasizes free expedited shipping and a self-serve portal for refills and plan changes.
Refunds, guarantees, and regulatory notes
SnagRx states a full refund if a prescription is declined and advertises a six-month weight-loss guarantee with terms. Pallas states clinicians refund in full if treatment is not right for you. Both include the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. SnagRx specifically flags that compounded medications are not FDA-approved finished products and encourages discussion with a provider about risks and benefits.
| Criteria | SnagRx | Pallas Health |
|---|---|---|
| Compounded semaglutide starting price | From $69/month on 12-month plan | $139 first month, then $199/month average |
| Tirzepatide starting price | From $119/month on 12-month plan | $179 first month, then $299/month average |
| Brand-name GLP-1s | Not offered; compounded only | Offers Wegovy, Ozempic, Zepbound, Mounjaro |
| Clinician care and check-ins | Telemed review by OpenLoop Health clinicians; review typically within 5 hours | Provider care, check-ins and messaging included; asynchronous in most states |
| Pharmacy and shipping | Named US 503A pharmacies; next-day UPS/FedEx shipping | Compounded in USA; free expedited discreet shipping |
| Refunds and guarantees | Full refund if prescription declined; six-month weight-loss guarantee (terms apply) | Refunded in full if clinician decides treatment is not right |
Review SnagRx terms and pharmacies
How the differences matter
If your priority is the lowest annual compounded price and a locked-in per-medication rate across titration, SnagRx positions itself for cost predictability on a 12-month commitment. If you want a clinician to choose between a brand-name pen and a compounded option and prefer integrated check-ins and a self-serve portal, Pallas Health provides both routes and ongoing care inside the plan price.
Conclusion — SnagRx vs Pallas Health
For patients comparing SnagRx vs Pallas Health: SnagRx is the lower-cost, compounded-only option with named pharmacies, fast stated clinician review and price locked for the life of treatment on its 12-month plan. Pallas Health is the clinician-choice platform that can prescribe FDA-approved brand-name GLP-1s or compounded alternatives with provider check-ins included and a 12-week renewal cadence for compounded plans. Both note that compounded medications are not FDA-approved and include clinician eligibility review.
Choose SnagRx if you want bottom-of-market compounded pricing on an annual plan, a named US 503A pharmacy network, and a price locked at every dose. Choose Pallas Health if you want a clinician to decide between brand-name pens and compounded medication, integrated provider check-ins and a single plan that includes care.